RT Journal Article
SR Electronic
T1 Uptake of same-day initiation of HIV treatment in Malawi, South Africa, and Zambia: the SPRINT retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.28.22282854
DO 10.1101/2022.11.28.22282854
A1 Amy Huber
A1 Kamban Hirasen
A1 Alana T Brennan
A1 Bevis Phiri
A1 Timothy Tchereni
A1 Lloyd Mulenga
A1 Prudence Haimbe
A1 Hilda Shakwelele
A1 Rose Nyirenda
A1 Bilaal Wilson Matola
A1 Andrews Gunda
A1 Sydney Rosen
YR 2022
UL http://medrxiv.org/content/early/2022/11/29/2022.11.28.22282854.abstract
AB Introduction Since 2017 global guidelines have recommended “same-day initiation” (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries in sub-Saharan Africa have incorporated a SDI option into national guidelines, but uptake of SDI is not well documented. We estimated average time to ART initiation at 12 public healthcare facilities in Malawi, 5 in South Africa, and 12 in Zambia.Methods We sequentially enrolled patients who were eligible to start ART between January 2018 and June 2019 and reviewed their medical records from the point of HIV treatment eligibility (HIV diagnosis or first HIV-related interaction with the clinic) to the earlier of treatment initiation or 6 months. We estimated the proportion of patients initiating ART at their original healthcare facilities on the same day or within 7, 14, 30, or 180 days of baseline, stratified by country and gender.Results We enrolled 826 patients in Malawi, 534 in South Africa, and 1,984 in Zambia. 88% of patients in Malawi, 57% in South Africa, and 91% in Zambia were offered and accepted SDI. In Malawi, most patients who did not receive SDI had also not initiated ART ≤ 6 months. In South Africa, an additional 13% of patients initiated ≤ 1 week, but 21% still had no record of initiation ≤ 6 months. Among those who did initiate within 6 months in Zambia, most started ≤ 1 week. There were no major differences by gender. Both WHO Stage III/IV and tuberculosis symptoms were associated with delays in ART initiation.Discussion As of 2020, uptake of same-day ART initiation was widespread, if not nearly universal, in Malawi and Zambia but was considerably less common in South Africa. Limitations of the study include pre-COVID-19 data that do not reflect pandemic adaptations and potentially missing data for Zambia. South Africa may be able to increase overall ART coverage by reducing numbers of patients who do not initiate ≤ 6 months.Registration Clinicaltrials.gov NCT04468399 (Malawi), NCT04170374 (South Africa), and NCT04470011 (Zambia).Competing Interest StatementLM, RN, and BWM hold positions in government agencies that have supervisory authority over the healthcare facilities involved in this study. No other competing interests were declared.Funding StatementThis research was supported by the Bill & Melinda Gates Foundation [OPP1192640] to Boston University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was provided by the Boston University Medical Campus Institutional Review Board (IRB) (Ref No. H-40354 (Malawi), H-39330 (South Africa) and H-40488 (Zambia)), the University of the Witwatersrand Human Ethics Research Committee in South Africa (Ref No. M200238 (Malawi), M190745 (South Africa) and M200599 (Zambia)), the National Health Sciences Research Committee in Malawi (Ref No. 20/04/2458) and the ERES Converge Institutional Review Board in Zambia (Ref No. 2020-Feb-009). The Ministry or Department of Health in all three countries and the National Health Research Authority in Zambia also approved the study. As this was a retrospective review of medical records and no identifiers were collected, informed consent was not sought.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the present study are owned by the Ministry of Health or Department of Health in each study country. Requests for data access can be made to the national research authority of each study country.